GSK 4348413A
Alternative Names: Gonorrhoea vaccine - GSK ; GSK-4348413; GSK-4348413A; Neisseria gonorrhoeae generalised modules for membrane antigens vaccine - GSK; Neisseria Gonorrhoeae GMMA vaccine - GSK; Ng GMMA vaccine - GSK; NgG vaccine - GSKLatest Information Update: 06 Feb 2024
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Gonorrhoea
Most Recent Events
- 06 Feb 2024 Phase-II clinical trials in Gonorrhoea (Prevention, In adults) (IM) (GlaxoSmithKline pipeline, February 2024)
- 26 Jul 2023 GSK 4348413A receives Fast Track designation for Gonorrhoea [IM] (Prevention, In adults) in USA, before July 2023
- 06 Dec 2022 Preclinical trials in Gonorrhoea (Prevention) in United Kingdom (IM) before December 2022